4//SEC Filing
Beaurang Pierre 4
Accession 0001209191-21-039810
CIK 0001549595other
Filed
Jun 10, 8:00 PM ET
Accepted
Jun 11, 4:10 PM ET
Size
14.0 KB
Accession
0001209191-21-039810
Insider Transaction Report
Form 4
Beaurang Pierre
Chief Business Officer
Transactions
- Sale
Common Stock
2021-06-10$30.01/sh−1,100$33,006→ 4,730 total - Exercise/Conversion
Common Stock
2021-06-10$1.11/sh+7,500$8,325→ 11,830 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-06-10−7,500→ 21,562 totalExercise: $1.11Exp: 2027-02-01→ Common Stock (7,500 underlying) - Sale
Common Stock
2021-06-10$29.15/sh−6,000$174,881→ 5,830 total - Sale
Common Stock
2021-06-10$30.90/sh−400$12,361→ 4,330 total
Holdings
- 116,666(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $28.64 and the highest price at which shares were sold was $29.62. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- [F3]Represents the weighted average sale price. The lowest price at which shares were sold was $29.67 and the highest price at which shares were sold was $30.57.
- [F4]Represents the weighted average sale price. The lowest price at which shares were sold was $30.765 and the highest price at which shares were sold was $30.95.
- [F5]The Reporting Person is a trustee of the Beaurang-Sligh Family Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- [F6]The option is fully vested.
Documents
Issuer
Nurix Therapeutics, Inc.
CIK 0001549595
Entity typeother
Related Parties
1- filerCIK 0001817226
Filing Metadata
- Form type
- 4
- Filed
- Jun 10, 8:00 PM ET
- Accepted
- Jun 11, 4:10 PM ET
- Size
- 14.0 KB